Inflammation and Endothelial Function: Direct Vascular Effects of Human C-Reactive Protein on Nitric Oxide Bioavailability

Background—Circulating concentrations of the sensitive inflammatory marker C-reactive protein (CRP) predict future cardiovascular events, and CRP is elevated during sepsis and inflammation, when vascular reactivity may be modulated. We therefore investigated the direct effect of CRP on vascular reactivity. Methods and Results—The effects of isolated, pure human CRP on vasoreactivity and protein expression were studied in vascular rings and cells in vitro, and effects on blood pressure were studied in rats in vivo. The temporal relationship between changes in CRP concentration and brachial flow-mediated dilation was also studied in humans after vaccination with Salmonella typhi capsular polysaccharide, a model of inflammatory endothelial dysfunction. In contrast to some previous reports, highly purified and well-characterized human CRP specifically induced hyporeactivity to phenylephrine in rings of human internal mammary artery and rat aorta that was mediated through physiological antagonism by nitric oxide (NO). CRP did not alter endothelial NO synthase protein expression but increased protein expression of GTP cyclohydrolase-1, the rate-limiting enzyme in the synthesis of tetrahydrobiopterin, the NO synthase cofactor. In the vaccine model of inflammatory endothelial dysfunction in humans, increased CRP concentration coincided with the resolution rather than the development of endothelial dysfunction, consistent with the vitro findings; however, administration of human CRP to rats had no effect on blood pressure. Conclusions—Pure human CRP has specific, direct effects on vascular function in vitro via increased NO production; however, further clarification of the effect, if any, of CRP on vascular reactivity in humans in vivo will require clinical studies using specific inhibitors of CRP.

[1]  D. Lang,et al.  C-Reactive Protein-Induced In Vitro Vasorelaxation Is an Artefact Caused by the Presence of Sodium Azide in Commercial Preparations , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[2]  Vilmundur Gudnason,et al.  C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. , 2004, The New England journal of medicine.

[3]  Mark B Pepys,et al.  C-reactive protein: a critical update. , 2003, The Journal of clinical investigation.

[4]  S. Ley,et al.  Therapeutic Inhibition of C-Reactive Protein-Novel Drugs, Novel Mechanisms , 2003 .

[5]  M. Clerici,et al.  Treatment, Immunological Changes and Pregnancy Outcome in HIV Infected Women , 2003 .

[6]  H. Krum,et al.  Urotensin II: a new player in vascular and myocardial disease? , 2003, Clinical science.

[7]  L. Lerman,et al.  C-Reactive Protein Relaxes Human Vessels In Vitro , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[8]  Sridevi Devaraj,et al.  Demonstration That C-Reactive Protein Decreases eNOS Expression and Bioactivity in Human Aortic Endothelial Cells , 2002, Circulation.

[9]  Ren-Ke Li,et al.  A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis , 2002, Circulation.

[10]  S. Verma,et al.  Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein , 2002, Circulation.

[11]  James T. Willerson,et al.  Modulation of C-Reactive Protein–Mediated Monocyte Chemoattractant Protein-1 Induction in Human Endothelial Cells by Anti-Atherosclerosis Drugs , 2001 .

[12]  J. Blusztajn,et al.  Acceleration of phosphatidylcholine synthesis and breakdown by inhibitors of mitochondrial function in neuronal cells: a model of the membrane defect of Alzheimer's disease. , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  James T. Willerson,et al.  Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.

[14]  S. Fichtlscherer,et al.  Elevated C-Reactive Protein Levels and Impaired Endothelial Vasoreactivity in Patients With Coronary Artery Disease , 2000, Circulation.

[15]  J. Connell,et al.  Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. , 2000, Clinical science.

[16]  Aroon D. Hingorani,et al.  Acute Systemic Inflammation Impairs Endothelium-Dependent Dilatation in Humans , 1999, Circulation.

[17]  W. Cliff,et al.  Coronary C-reactive protein distribution: its relation to development of atherosclerosis. , 1999, Atherosclerosis.

[18]  A. Hingorani,et al.  Enhancement of endothelium-dependent vasodilatation by oestradiol 17-beta: Role of the pterin pathway , 1999 .

[19]  A. Hingorani,et al.  Cytokine-induced venodilatation in humans in vivo: eNOS masquerading as iNOS. , 1999, Cardiovascular Research.

[20]  W. Koenig,et al.  C-reactive protein frequently colocalizes with the terminal complement complex in the intima of early atherosclerotic lesions of human coronary arteries. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[21]  W. Roos,et al.  Development of a new microparticle‐enhanced turbidimetric assay for C‐reactive protein with superior features in analytical sensitivity and dynamic range , 1998, Journal of clinical laboratory analysis.

[22]  S. Thompson,et al.  Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.

[23]  I. Sartori Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris , 1996 .

[24]  W E Haefeli,et al.  Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. , 1995, Circulation.

[25]  J. Cooper,et al.  The Effects of Quality and Timing of Venepuncture on Markers of Blood Coagulation in Healthy Middle-aged Men , 1995, Thrombosis and Haemostasis.

[26]  A. Rebuzzi,et al.  The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.

[27]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[28]  Harry,et al.  C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. , 1993, Blood.

[29]  J. K. Lloyd,et al.  Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis , 1992, The Lancet.

[30]  M. Pepys,et al.  Serum amyloid P component in chronic renal failure and dialysis. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[31]  M. Pepys,et al.  Isolation of human C-reactive protein and serum amyloid P component. , 1982, Journal of immunological methods.

[32]  M. Pepys,et al.  Solid phase radioimmunoassays for human C-reactive protein. , 1981, Clinica chimica acta; international journal of clinical chemistry.

[33]  M. Pontet,et al.  One step preparation of both human C‐reactive protein and CIt , 1978, FEBS letters.

[34]  H. Sies,et al.  On the state of mitochondria in perfused liver: Action of sodium azide on respiratory carriers and respiration , 1969, FEBS letters.